Company intelligence / Profile preview

Cord Blood Registry

Los Angeles, California, United Statesfacebook.com ↗

Ownership: Private
Development stage: Commercial

Overview

CBR has released over 700 cord blood samples for use by client families, with 100% of samples deemed suitable for use by treating physicians. 80% of released cord blood units have been used for experimental regenerative therapies[4].

Therapeutic areas: ImmunologyNeurologyHematology
Modalities: Stem cell therapies, particularly hematopoietic stem cells from cord blood and mesenchymal stem cells from cord tissue
Industry: Biotech

Partnerships

NantKwest (for COVID-19 treatment development)research institutions for FDA-regulated clinical trials

Beyond the preview

Go deeper on Cord Blood Registry.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cord Blood Registry.

Explore the full profile